The financials
Rhythm Pharmaceuticals, Inc. by the numbers
Rhythm Pharmaceuticals, Inc. (RYTM) reported revenue of $71M in Q2 2026 (quarter ended Jun 30, 2026), up 47% from the same quarter a year earlier. That came with a gross margin of 87% and net loss of $49M. For the full year FY2025, revenue was $190M (+46% year on year) and net income −$197M. Its largest region in Q2 2026 was United States at $51M, 72% of the disclosed total, well ahead of Non Us at 28%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $71M | $49M | +47% |
| Gross profit | $62M | $43M | +45% |
| Operating income | −$49M | −$45M | n/a |
| Net income | −$49M | −$47M | n/a |
| Diluted EPS | −$0.73 | −$0.75 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $51M | 72% |
| Non Us | $20M | 28% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q2 2026Total $71.3M (+19%)
United States grew +59% year on yearNon Us +23% year on year
Segment Latestquarter on quarteryear on year
- United States$51.0M$51.0MQoQ +38%year on year +59%+38%+59%
- Non Us$20.3M$20.3MQoQ -13%year on year +23%-13%+23%